Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for TLX591-CDx
Telix Pharmaceuticals Limited is pleased to announce that it has received positive feedback from the US Food and Drug Administration (FDA) regarding its submission of a New Drug Application (NDA) for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11).
Telix’s clinical data proposed for its NDA submission is based on a combination of prospective and retrospective data, including imaging data from the Novartis VISION study. The FDA has provided detailed feedback on the clinical briefing package for the efficacy data, which the Company expects to be able to satisfy, based on the planned submission dataset.
To read the full media release click here.
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...
FDA Grants Orphan Drug Designation for TLX102
Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...
Half Year Shareholder Update
Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update
First patient dosed in renal cancer imaging study in Japan
Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...
Telix H1 2020 Results and Company Update Conference Call
Melbourne (Australia) – 11th August 2020. Telix will hold an investor conference call to present the Company’s H1 2020 financial...
Drug Master File for Glioblastoma Therapy Product Filed with FDA
Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...
Activities Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th...
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)